ABBV: Other company developments

Item 8.01. Other Events. On August 4, 2026, AbbVie Inc. (“ AbbVie ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein (collectively, the “ Underwriters ”), pursuant to which AbbVie agreed to issue and sell to the Underwriters $500,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “ Floating Rate Notes ”), $1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028 (the “ 2028 Notes ”), $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2030 (the “ 2030 Notes ”), $1,500,000,000 aggregate principal amount of its 4.875% senior notes due 2031 (the “ 2031 Notes ”), $1,250,000,000 aggregate principal amount of its 5.050% senior notes due 2033 (the “ 2033 Notes ”), $1,500,000,000 aggregate principal amount of its 5.300% senior notes due 2036 (the “ 2036 Notes ”), $1,000,000,000 aggregate principal amount of its 5.450% senior notes due 2038 (the “ 2038 Notes ”), $1,500,000,000 aggregate principal amount of its 6.000% senior notes due 2056 (the “ 2056 Notes ”) and $500,000,000 aggregate principal amount of its 6.100% senior notes due 2066 (the “ 2066 Notes ” and, together with the Floating Rate Notes, the 2028 Notes, the 2030 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes, the 2038 Notes and the 2056 Notes, the “ Notes ”). The price to the public was 100% of the principal amount for the Floating Rate Notes, 99.970% of the principal amount for the 2028 Notes, 99.862% of the principal amount for the 2030 Notes, 99.977% of the principal amount for the 2031 Notes, 99.88